i-RNA Corporation joins Johnson & Johnson Innovation - JLABS as a new resident company in Toronto!

i-RNA Corporation, a company dedicated to the development of new innovative methods for the treatment and diagnosis of diabetic retinopathy, a leading cause of blindness worldwide, announced that it has been selected as a resident company of Johnson & Johnson Innovation - JLABS @ Toronto.

JLABS is one of the largest global networks of life science startups, investors, and corporate partners that support the incubation, growth and optimization of early stage R&D through the innovation ecosystem, including industry connections, entrepreneurial programs, access to capital-efficient resources and lab space. i-RNA Corporation is seeking to accelerate the innovation of its lncRNA-based therapeutics and diagnostics to commercialization and bring to patients around the world.

Our mission is to improve eye diseases outcomes and prognosis by enhancing patient outcome and compliance whilst lowering healthcare costs. Our patented technology is a first-in-class lncRNA-based drug candidate that is potentially longer lasting, more effective, more robust and less expensive than existing intraocular injection of anti-VEGF treatments. We have demonstrated in mice and rats models that the treatment can be delivered as an eyedrop. We believe that our solution can make a difference in the lives of millions of people who suffer from vision loss and blindness worldwide.      

We are excited to join the JLABS community and will continue to advance our R&D activities in this passionate and vibrant ecosystem as we work towards our vision to have a better world seem better by everyone.

About i-RNA

Based in London, Ontario, i-RNA Corporation is an early-stage spin-off company from the University of Western Ontario, that is dedicated to the development of innovative methods for the treatment and diagnosis of diabetic retinopathy, a leading cause of blindness worldwide. The company is developing proprietary first-in-class lncRNA-based drugs that are potentially longer lasting, more effective, more robust and less expensive than existing treatments for diabetic retinopathy and other ocular diseases.